Drug insight: statins for nonischemic heart failure--evidence and potential mechanisms (Q30443238)

21 June 2017

0 references

1 reference

title

Drug insight: statins for nonischemic heart failure--evidence and potential mechanisms (English)

1 reference

21 June 2017

1 reference

Valentín Fuster Carulla

object named as

Valentin Fuster

3

0 references

author name string

Michael J Lipinski

1

1 reference

21 June 2017

Antonio Abbate

2

1 reference

21 June 2017

George W Vetrovec

4

1 reference

21 June 2017

publication date

1 April 2007

1 reference

Nature Clinical Practice Cardiovascular Medicine

21 June 2017

published in

1 reference

21 June 2017

volume

4

1 reference

21 June 2017

issue

4

1 reference

21 June 2017

page(s)

196-205

1 reference

Simvastatin restores endothelial NO-mediated vasorelaxation in large arteries after myocardial infarction

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

Statin therapy restores sympathovagal balance in experimental heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Anti-inflammatory effects of statins: clinical evidence and basic mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Effect of statins and white blood cell count on mortality in patients with ischemic left ventricular dysfunction undergoing percutaneous coronary intervention.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Statins associated with reduced mortality in patients admitted for congestive heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Statins and mortality among elderly patients hospitalized with heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Statin therapy and risks for death and hospitalization in chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Statin use and survival in patients with chronic heart failure--results from two observational studies with 5200 patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Statin use and survival outcomes in elderly patients with heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Progression of coronary artery disease in non-ischemic dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

The endotoxin-lipoprotein hypothesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Prognostic significance of serum cholesterol levels in patients with idiopathic dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

The importance of abnormalities of liver function tests in predicting mortality in chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Relation of Serum Total Cholesterol, C-Reactive Protein Levels, and Statin Therapy to Survival in Heart Failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Natriuretic peptides in unstable coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Lovastatin decreases coenzyme Q levels in humans

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

The effect of pravastatin and atorvastatin on coenzyme Q10.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

The impact of coenzyme Q10 on systolic function in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Early and Sustained Survival Benefit Associated With Statin Therapy at the Time of Percutaneous Coronary Intervention

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

White blood cell count predicts reduction in coronary heart disease mortality with pravastatin

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

The effects of atorvastatin (10 mg) on systemic inflammation in heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Differential effects of statins on serum CRP levels: implications of recent clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

The effect of statins on mortality in patients with bacteremia

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Coronary endothelial dysfunction in patients with acute-onset idiopathic dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

The pathogenesis of atherosclerosis: a perspective for the 1990s

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Nitric oxide insufficiency, platelet activation, and arterial thrombosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

The natural history of idiopathic dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Pravastatin reduces thrombogenicity by mechanisms beyond plasma cholesterol lowering.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Impact of hydroxymethylglutaryl coenzyme A reductase inhibition on left ventricular remodeling in patients with acute anterior myocardial infarction after primary coronary angioplasty.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

ACE inhibitors and statins acutely improve endothelial dysfunction of human coronary arterioles

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Oncogenic src, raf, and ras stimulate a hypertrophic pattern of gene expression and increase cell size in neonatal rat ventricular myocytes

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Clinical trials update from the American College of Cardiology: Darbepoetin alfa, ASTEROID, UNIVERSE, paediatric carvedilol, UNLOAD and ICELAND.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Simvastatin Normalizes Autonomic Neural Control in Experimental Heart Failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Short-term adjuvant atorvastatin improves frequency domain indices of heart rate variability in stable systolic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

The importance of heart rate recovery in patients with heart failure or left ventricular systolic dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Decreased heart rate recovery in patients with heart failure: effect of fluvastatin therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Statins inhibit beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes via a Rac1-dependent mechanism.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Impact of Statin Therapy on Clinical Outcomes in Chronic Heart Failure Patients According to Beta-Blocker Use: Results of CIBIS II

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Atorvastatin completely inhibits VEGF-induced ACE upregulation in human endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Effect of intensive versus moderate lipid lowering on endothelial function and vascular responsiveness to angiotensin II in stable coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0855

7 January 2021

Identifiers

DOI

10.1038/NCPCARDIO0855

1 reference

21 June 2017

1 reference